Controls serum phosphorus. Sold as Renvela. Every FDA application for this active ingredient: 2 branded and 26 generic.
As of Nov 15, 2026, FDA lists 28 applications for Sevelamer Carbonate (sold as Renvela), first approved Oct 19, 2007, with 2 new uses approved and 0 published complete response letters.
| Sevelamer Carbonate | Part D | $3.7M | -97% | 14,842 |
| Renvela | Part D | $110K | -100% | 55 |
| Tenapanor in Maintenance Hemodialysis PatientsHyperphosphatemia, Maintenance Hemodialysis · Huashan Hospital | — | Not yet recruiting | Oct 20, 2026 |
| Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)Coronavirus Infection (COVID-19), Pulmonary Arterial Hypertension · Duke University | — | Recruiting | Feb 20, 2020 |
| Oct 19, 2007 | RenvelaNDA 22127 · New dosage form | Sanofi | 6 | Discontinued |
| Aug 12, 2009 | RenvelaNDA 22318 · New dosage form | Genzyme | 5 | Discontinued |
| Jun 13, 2017 | Sevelamer CarbonateANDA 207624 | Aurobindo Pharma | 2 | Marketed |
| Jul 17, 2017 | Sevelamer CarbonateANDA 207179 | Aurobindo Pharma | 3 | Marketed |
| Sep 29, 2017 | Sevelamer CarbonateANDA 206094 | Dr Reddys | 3 | Marketed |
| Oct 23, 2017 | Sevelamer CarbonateANDA 90975 | Impax Labs Inc | 0 | Discontinued |
| Oct 26, 2017 | Sevelamer CarbonateANDA 203860 | Invagen Pharms | 2 | Marketed |
| Nov 28, 2017 | Sevelamer CarbonateANDA 207288 | Amneal Pharms Co | 1 | Marketed |
| Mar 20, 2018 | Sevelamer CarbonateANDA 200959 | Quagen | 1 | Marketed |
| Oct 25, 2018 | Sevelamer CarbonateANDA 210464 | Dr Reddys | 1 | Marketed |
| Nov 29, 2018 | Sevelamer CarbonateANDA 204451 | Rising | 1 | Marketed |
| Apr 9, 2020 | Sevelamer CarbonateANDA 212970 | Epic Pharma LLC | 1 | Discontinued |
| Aug 5, 2020 | Sevelamer CarbonateANDA 201069 | Strides Pharma Intl | 0 | Discontinued |
| Aug 11, 2020 | Sevelamer CarbonateANDA 207759 | Zydus Pharms | 0 | Marketed |
| Nov 20, 2020 | Sevelamer CarbonateANDA 211316 | Impax | 0 | Marketed |
| Jan 14, 2021 | Sevelamer CarbonateANDA 204600 | Chartwell Rx | 0 | Discontinued |
| May 17, 2021 | Sevelamer CarbonateANDA 209374 | Bionpharma | 1 | Marketed |
| Dec 23, 2021 | Sevelamer CarbonateANDA 201513 | Lupin | 0 | Discontinued |
| Feb 7, 2022 | Sevelamer CarbonateANDA 215537 | Micro Labs | 0 | Discontinued |
| Mar 2, 2023 | Sevelamer CarbonateANDA 217319 | Chartwell Rx | 0 | Marketed |
| Apr 19, 2023 | Sevelamer CarbonateANDA 206100 | Macleods Pharms | 1 | Marketed |
| Sep 8, 2023 | Sevelamer CarbonateANDA 211917 | Strides Pharma Intl | 0 | Marketed |
| Apr 25, 2024 | Sevelamer CarbonateANDA 207291 | Macleods Pharms | 0 | Marketed |
| May 9, 2024 | Sevelamer CarbonateANDA 211915 | Strides Pharma | 0 | Marketed |
| Jul 12, 2024 | Sevelamer CarbonateANDA 206234 | Invagen Pharms | 0 | Discontinued |
| Oct 24, 2024 | Sevelamer CarbonateANDA 215998 | Shandong Xinhua | 0 | Marketed |
| Feb 27, 2025 | Sevelamer CarbonateANDA 215909 | Torrent | 0 | Discontinued |
| Oct 27, 2025 | Sevelamer CarbonateANDA 219931 | Navinta LLC | 0 | Marketed |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Sanofi
Aurobindo Pharma
Impax Labs Inc
Strides Pharma Intl
Zydus Pharms
Lupin